References
Fowler Jr VG, Miro JM, Hoen B, et al. Staphylococcus aureus endocarditis: a consequence of medical progress. JAMA. 2005;293(24):3012–21.
Cosgrove SE, Fowler Jr VG. Management of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008;46 Suppl 5:S386–93.
Fowler Jr VG, Boucher HW, Corey GR, et al. Daptomycin versus standard therapy for bacteremia and endocarditis caused by Staphylococcus aureus. N Engl J Med. 2006;355(7):653–65.
Rybak MJ, Albrecht LM, Boike SC, Chandrasekar PH. Nephrotoxicity of vancomycin, alone and with an aminoglycoside. J Antimicrob Chemother. 1990;25(4):679–87.
Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. Ann Intern Med. 1982;97(4):496–503.
Mandell GL, Kaye D, Levison ME, Hook EW. Enterococcal endocarditis. An analysis of 38 patients observed at the New York Hospital-Cornell Medical Center. Arch Intern Med. 1970;125(2):258–64.
Baddour LM, Wilson WR, Bayer AS, et al. Infective endocarditis: diagnosis, antimicrobial therapy, and management of complications: a statement for healthcare professionals from the Committee on Rheumatic Fever, Endocarditis, and Kawasaki Disease, Council on Cardiovascular Disease in the Young, and the Councils on Clinical Cardiology, Stroke, and Cardiovascular Surgery and Anesthesia, American Heart Association: endorsed by the Infectious Diseases Society of America. Circulation. 2005;111(23):e394–434.
Levine DP, Fromm BS, Reddy BR. Slow response to vancomycin or vancomycin plus rifampin in methicillin-resistant Staphylococcus aureus endocarditis. Ann Intern Med. 1991;115(9):674–80.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Levine, D.P. Synergy: A Cautionary Tale. Curr Infect Dis Rep 13, 303–304 (2011). https://doi.org/10.1007/s11908-011-0185-9
Published:
Issue Date:
DOI: https://doi.org/10.1007/s11908-011-0185-9